Abstract： Objective： To explore the level of fecal calprotectin (CPT) and lactoferrin (LF) in patients with Parkinson′s disease (PD), and analyze their correlation with clinical symptoms of PD and serum inflammatory factors. Methods： A total of 55 PD patients who first visited the Department of Neurology, the Fourth Affiliated Hospital of Jiangsu University from January 2019 to January 2022 were selected (PD group), and 48 healthy subjects during the same period (control group) were enrolled in the study. The general data of the two groups were collected and compared, and the fecal CPT and LF levels of the two groups as well as the serum tumor cell necrosis factorα (TNFα) and interleukin6 (IL6) levels of the PD group were detected. After 2 months of treatment, fecal CPT and LF levels in the PD group were measured again. The PD group was scored on the Unified Parkinson′s Disease Rating Scale (UPDRS) before and after treatment. Pearson correlation was used to analyze the correlation between fecal CPT, LF levels and UPDRS scores in the PD group, as well as the correlation between ΔCPT, ΔLF and ΔUPDRS scores. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of fecal CPT and LF levels for PD. Results： There were no significant differences in clinical characteristics between PD group and control group (all P>0.05). Before treatment, the fecal levels of CPT and LF in PD group were significantly higher than those in control group (all P<0.01). After treatment, the fecal levels of CPT and LF in PD group, as well as the UPDRS score, were significantly declined compared with those before treatment (all P<0.01). The UPDRS score had a positive correlation with fecal CPT and LF (r=0.605, 0.619, both P<0.01). ΔUPDRS score had a positive correlation with ΔCPT and ΔLF (r=0.735, 0.760, both P<0.01). The fecal CPT and LF levels in PD group before treatment were positively correlated with serum TNF-α and IL-6 respectively (CPT: rTNF-α=0.689, rIL-6=0.591; LF: rTNF-α=0.673, rIL-6=0.616; all P<0.01). The areas under the ROC curves of fecal CPT and LF were 0.892 and 0.874, the sensitivities were 89.58% and 88.32%, and the specificities were 83.29% and 74.55%, respectively. Conclusion： Fecal CPT and LF levels are increased in PD patients, which is correlated with symptom scores and serum TNF-α and IL-6 levels.
Key words：
收稿日期: 2023-02-08
基金资助: 镇江市社会发展项目(SH2023070)
通讯作者:
钱进军(通讯作者)，主任医师，E-mail: qian-jinjun@163.com
作者简介: 赵晶(1980—)，女，硕士，江苏镇江人，副主任医师，主要从事脑血管病研究
引用本文:
赵晶， 束瑜， 钱进军. 帕金森病患者粪便钙卫蛋白和乳铁蛋白水平及其与血清IL-6和TNF-α水平的相关性分析[J]. 江苏大学学报:医学版, 2024, 34(02): 156-160.
ZHAO Jing, SHU Yu, QIAN Jinjun. Level of fecal calprotectin and lactoferrin in patients with Parkinson′s disease and their correlation with serum IL-6 and TNF-α levels. Journal of Jiangsu University(Medicine Edition), 2024, 34(02): 156-160.
1］Reich SG, Savitt JM. Parkinson′s disease［J］. Med Clin North Am, 2019, 103(2): 337-350.
［2］Wang Q, Luo Y, Ray Chaudhuri K, et al. The role of gut dysbiosis in Parkinson′s disease: mechanistic insights and therapeutic options［J］. Brain, 2021, 144(9): 2571-2593.
［3］Hirayama M, Ohno K. Parkinson′s disease and gut microbiota［J］. Ann Nutr Metab, 2021, 77 Suppl 2: 28-35.
［4］Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function［J］. Gut, 2021, 70(10): 1978-1988.
［5］Liu N, Feng G, Zhang X, et al. The functional role of lactoferrin in intestine mucosal immune system and inflammatory bowel disease［J］. Front Nutr, 2021, 8: 759507.
［6］Park SY, Lee SP, Kim WJ. Fecal calprotectin is increased in stroke［J］. J Clin Med, 2021, 11(1): 159.
［8］Li Y, Chen Y, Jiang L, et al. Intestinal inflammation and Parkinson′s disease［J］. Aging Dis, 2021, 12(8): 2052-2068.
［9］Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson′s diseaselike symptoms in Pink1-/- mice［J］. Nature, 2019, 571(7766): 565-569.
［10］Sangarapillai K, Norman BM, Almeida QJ. An equation to calculate UPDRS motor severity for online and rural assessments of Parkinson′s［J］. Parkinsonism Relat Disord, 2022, 94: 96-98.
